马拉维儿童一线抗逆转录病毒治疗中病毒学失败与HIV耐药突变高发
该前瞻性队列纳入35例接受一线抗逆转录病毒治疗(ART)的马拉维HIV感染儿童,随访12个月,6个月和12个月检测病毒载量,12个月做基因型耐药检测。结果显示病毒学失败(VF)达66%(23/35),耐药突变(DRM)达44%(15/34),均为非核苷类逆转录酶抑制剂(NNRTI)耐药,12%(4/34)为NNRTI/NRTI双类耐药;对现行一线方案敏感性下降者占41%(14/34)。
要点
- 马拉维儿童一线ART 12个月内VF达66%,DRM达44%,以NNRTI耐药为主。
- 12%儿童出现NNRTI/NRTI双类耐药,41%对现行一线方案敏感性下降。
- 奈韦拉平高水平耐药最常见,占26%。
核心结论
- 马拉维一线ART儿童中VF和DRM发生率惊人地高,需加强程序性评估并检测耐药以调整一线和二线方案。
研究设计与样本
- 前瞻性队列研究,纳入35例ART初治的马拉维HIV感染儿童,接受一线治疗并每月随访。
- 6个月和12个月采血检测病毒载量,12个月行基因型耐药检测,并用Stanford算法及基因型敏感性评分(GSS)评估NRTI和NNRTI敏感性。
- VF定义为至少一次病毒载量>1000 copies/mL或ART 6个月后死亡。
主要发现
- 12个月随访期间VF发生于66%(23/35)的儿童。
- DRM检出率为44%(15/34),全部为NNRTI耐药,12%(4/34)为NNRTI/NRTI双类耐药。
- 对现行一线方案敏感性下降(DRM且GSS<3)者占41%(14/34)。
- 高水平耐药最常见于奈韦拉平,占26%(9/34)。
关键数值与推荐
- VF定义:至少一次病毒载量>1000 copies/mL或ART 6个月后死亡。
- 敏感性下降定义:存在DRM且GSS<3。
- DRM检出44%(15/34),NNRTI耐药100%(15/15),双类耐药12%(4/34),对一线方案敏感性下降41%(14/34),奈韦拉平高水平耐药26%(9/34)。
临床怎么用
- 撒哈拉以南非洲儿童HIV项目应重视程序性VF评估,并纳入DRM检测以指导一线及二线方案调整。
- 对一线治疗儿童应关注NNRTI耐药及双类耐药风险,避免耐药广泛传播。
局限性
- 样本量小(35例),来自单一国家队列,结果外推需谨慎。
- 原文未报告随访依从性、具体ART方案构成及耐药检测失败情况等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Drug resistance mutations (DRMs) increasingly jeopardize paediatric HIV programmes in sub-Saharan Africa. As individual monitoring of DRMs and viral loads has limited availability, population data on DRMs are essential to determine first-line susceptibility. Paediatric data from sub-Saharan Africa are scarce and unavailable for Malawi. OBJECTIVES: To determine the prevalence of virological failure (VF) and DRMs among ART-naive HIV-infected Malawian children during the first year of first-line ART. METHODS: In a prospective cohort of HIV-infected Malawian children, on first-line treatment, children were followed monthly; blood was collected for viral load testing (6 and 12 months) and genotypic resistance testing (12 months). VF was defined as at least one viral load >1000 copies/mL or death after 6 months of ART. DRMs were identified and susceptibility to NRTIs and NNRTIs was scored using the Stanford algorithm and by calculating genotypic susceptibility scores (GSSs). RESULTS: VF occurred in 66% (23/35) of the children during 12 months of follow-up. DRMs were detected in 44% (15/34); all had NNRTI resistance and 12% (4/34) had dual-class NNRTI/NRTI resistance. Reduced susceptibility (DRMs and GSS <3) was seen in 41% (14/34) to their current first-line regimen. High-level resistance was most common for nevirapine [26% (9/34)]. CONCLUSIONS: In this first report on VF and DRMs in children on first-line ART in Malawi, the rates of VF and DRMs were alarmingly high. Paediatric HIV programmes in sub-Saharan Africa should emphasize programmatic evaluation of VF and include detection of DRMs to adjust and design adequate first- and second-line regimens and prevent widespread resistance in children.
引用
- Huibers MHW, Moons P, Cornelissen M, et al. High prevalence of virological failure and HIV drug mutations in a first-line cohort of Malawian children. J Antimicrob Chemother. 2018. PMID: 30169653. doi:10.1093/jac/dky348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。